Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc.

NASDAQ:ACRS

Overview | Financials
Company Name Aclaris Therapeutics, Inc.
Symbol ACRS
Currency USD
Price 2.9
Market Cap 207,149,610
Dividend Yield 0%
52-week-range 0.856 - 5.17
Industry Diagnostics & Research
Sector Healthcare
CEO Dr. Douglas J. Manion Frcp(C), M.D.
Website https://www.aclaristx.com

An error occurred while fetching data.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research

Related Stocks

Enanta Pharmaceuticals, Inc. logo

Enanta Pharmaceuticals, Inc.

ENTA

6.1 USD

Kura Oncology, Inc. logo

Kura Oncology, Inc.

KURA

8.86 USD

FibroGen, Inc. logo

FibroGen, Inc.

FGEN

0.499 USD

Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc.

SANA

1.75 USD

Mirum Pharmaceuticals, Inc. logo

Mirum Pharmaceuticals, Inc.

MIRM

42.17 USD

Cutera, Inc. logo

Cutera, Inc.

CUTR

0.327 USD

Syndax Pharmaceuticals, Inc. logo

Syndax Pharmaceuticals, Inc.

SNDX

13.07 USD

Avid Bioservices, Inc. logo

Avid Bioservices, Inc.

CDMO

12.26 USD

Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc.

KROS

16.71 USD

Financials

Numbers are in millions USD

Numbers are in millions USD